



Revance Earns Great Place to Work® Certification for Second Year

October 2, 2019

NEWARK, Calif.--(BUSINESS WIRE)--Oct. 2, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the company is certified as a great workplace by the independent analysts at Great Place to Work® for the second consecutive year.

"At Revance we aspire to a culture that embodies speed, audacity, grit, and empathy," said Justin Ford, Vice President, Human Resources and Head of People. "To us, this means empowering employees to make a difference, and making them feel valued along the way."

Revance earned the honor based on a comprehensive set of ratings provided by its employees in anonymous surveys.

"Behind every great product is an incredible group of people," said Dan Browne, President and Chief Executive Officer of Revance. "We act quickly, think big, and are persistent and unrelenting. But most importantly, we care about our people. By fusing cutting-edge science with the entrepreneurial spirit of Silicon Valley, our team is daring to make a difference by introducing aesthetic and therapeutic treatments that can meaningfully transform neuromodulator patients' ability to look, feel and perform their best."

For more information about Revance and its culture, visit www.revance.com/careers/.

About Great Place to Work Institute

Great Place to Work is a global research, consulting and training firm that helps organizations create and sustain great workplaces through the development of high-trust workplace cultures. Great Place to Work serves business, non-profits and government agencies in 45 countries on all six continents. In the US, Great Place to Work produces the annual FORTUNE 100 Best Companies to Work For list and Great Place to Work Best Small & Medium Workplaces list published by Entrepreneur.com. Join the movement of Great Place to Work at www.greatplacetowork.com.

About Revance Therapeutics, Inc.

Revance Therapeutics is a Silicon Valley-based biotechnology company, pioneering new innovations in neuromodulators for aesthetic and therapeutic indications. Revance's lead product candidate, DaxibotulinumtoxinA for Injection (DAXI), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines, delivering unprecedented efficacy and long-lasting duration of effect, and is pursuing U.S. regulatory approval in 2020. Revance is also evaluating DAXI in forehead lines and lateral canthal lines (crow's feet), as well as in three therapeutic indications - cervical dystonia, adult upper limb spasticity and plantar fasciitis, with plans to study migraine. Beyond DAXI, Revance has begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

BOTOX® is a registered trademark of Allergan, Inc.

Great Place to Work is a register trademark of Great Place to Work® Institute.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to the process and timing of, and ability to complete, current and anticipated future clinical development of our investigational drug product candidates, including but not limited to initiation and design of clinical studies for current and future indications, including the timing and results of the SAKURA 3 study of RT002, related results and reporting of such results; statements about our business strategy, timeline and other goals and market for our anticipated products, plans and prospects; including our pre-commercialization plans; and statements about our ability to obtain regulatory approval, including the timing of potential BLA filing for RT002 to treat glabellar (frown) lines; and potential benefits of our drug product candidates and our technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; our ability to obtain funding for our operations; our plans to research, develop, and commercialize our drug product candidates; our ability to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to successfully commercialize our drug product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our drug product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Revance's periodic filings with the Securities and Exchange Commission (the "SEC"), including factors described in the section entitled "Risk Factors" of our quarterly report on Form 10-Q filed August 3, 2018. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191002005497/en/>

Source: Revance Therapeutics, Inc.

INVESTORS

Revence Therapeutics, Inc.:
Jeanie Herbert, 714-325-3584
jherbert@revance.com

or

Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620
laurence@gilmartinir.com

MEDIA

Revence Therapeutics, Inc.:
Sara J. Fahy, 949-887-4476
sfahy@revance.com

or

General Media:

Y&R:

Jenifer Slaw, 347-971-0906
jenifer.slaw@YR.com

or

Trade Media:

Nadine Tosk, 504-453-8344
nadinepr@gmail.com